Literature DB >> 3317495

Multiple cerebral metastases: detectability with Gd-DTPA-enhanced MR imaging.

E J Russell1, G K Geremia, C E Johnson, M S Huckman, R G Ramsey, J Washburn-Bleck, D A Turner, M Norusis.   

Abstract

Sixteen patients with suspected cerebral metastases were studied with magnetic resonance (MR) imaging before and after the intravenous administration of 0.1 mmol/kg of gadolinium diethylenetriaminepenta-acetic acid. The images were interpreted blindly by two neuroradiologists; all clinical, radiologic (computed tomographic and MR imaging), and pathologic data were reviewed to arrive at a final "best diagnosis," which was then compared with the prior blinded interpretations. Of seven patients found to have multiple metastases, six (86%) had at least one tumor nodule depicted by postinfusion MR imaging that was missed by one or both observers on review of preinfusion images alone. Lesions missed on preinfusion studies were usually small nodules hidden by or not detected next to regions of high-signal edema thought to be related to the adjacent tumor nodule. The authors believe that contrast enhancement improves detection of metastatic foci with MR imaging and that the findings indicate broader implications for the detection of multiple lesions from other causes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3317495     DOI: 10.1148/radiology.165.3.3317495

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  22 in total

1.  New applications of MR contrast agents in neuroradiology.

Authors:  G Sze
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

2.  Value of contrast enhanced CT scanning in the non-trauma emergency room patient.

Authors:  L P Wood; M Parisi; I J Finch
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

Review 3.  Nuclear magnetic resonance in clinical pharmacology and measurement of therapeutic response.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

4.  Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases.

Authors:  Timothy J Kaufmann; Marion Smits; Jerrold Boxerman; Raymond Huang; Daniel P Barboriak; Michael Weller; Caroline Chung; Christina Tsien; Paul D Brown; Lalitha Shankar; Evanthia Galanis; Elizabeth Gerstner; Martin J van den Bent; Terry C Burns; Ian F Parney; Gavin Dunn; Priscilla K Brastianos; Nancy U Lin; Patrick Y Wen; Benjamin M Ellingson
Journal:  Neuro Oncol       Date:  2020-06-09       Impact factor: 12.300

Review 5.  MR imaging of cerebral tumors: state of the art and work in progress.

Authors:  H P Higer; P Pedrosa; M Schuth
Journal:  Neurosurg Rev       Date:  1989       Impact factor: 3.042

6.  MRI in detection of brain metastases at initial staging of small-cell lung cancer.

Authors:  M van de Pol; A G van Oosterhout; J T Wilmink; G P ten Velde; A Twijnstra
Journal:  Neuroradiology       Date:  1996-04       Impact factor: 2.804

7.  Neuron-specific enolase as a marker of brain metastasis in patients with small-cell lung carcinoma.

Authors:  M van de Pol; A Twijnstra; G P ten Velde; P P Menheere
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  Intracranial metastases of hepatocellular carcinoma: CT and MRI.

Authors:  K Murakami; S Nawano; N Moriyama; R Sekiguchi; M Satake; H Fujimoto; T Ichikawa
Journal:  Neuroradiology       Date:  1996-05       Impact factor: 2.804

9.  Time-delayed contrast-enhanced MRI improves detection of brain metastases: a prospective validation of diagnostic yield.

Authors:  Or Cohen-Inbar; Zhiyuan Xu; Blair Dodson; Tanvir Rizvi; Christopher R Durst; Sugoto Mukherjee; Jason P Sheehan
Journal:  J Neurooncol       Date:  2016-08-27       Impact factor: 4.130

Review 10.  The clinical application of radiopharmaceuticals.

Authors:  N E Leeds
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.